Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8811099 | 0.84 | ESR1 (0.41) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL6736322 | 0.82 | ESR1 (0.42) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL186689 | 0.80 | TRPV4 (0.42) | ESR1ESR2KDM4EALDH1A1TRPV4 | |
| SCHEMBL8811100 | 0.80 | ESR1 (0.42) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL21887348 | 0.78 | AR (0.40) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL29176704 | 0.78 | ESR1 (0.38) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL17929420 | 0.78 | AR (0.37) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL21811303 | 0.78 | IL4 (0.38) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL423158 | 0.78 | AR (0.37) | ESR1ESR2ARKDM4EALDH1A1 | |
| SCHEMBL26659446 | 0.78 | ESR1 (0.45) | ESR1ESR2ARKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2744499-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2790511-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2015179697-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-9062070-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2203219-B1 | SUBSTITUTED BENZAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2015-02-25 | — | — | EP | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| WO-2013028474-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2203219-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | Biota Europe Ltd (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009040507-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040507-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ELANE, MMP8, NISCH | ESR1 3565/4885ESR2 2974/4885AR 4855/4885 |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | ALK, CBR3, CBR1 | ESR1 1617/4885ESR2 579/4885AR 2528/4885 |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | ESR1 4435/4885ESR2 2275/4885AR 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.